Related Experiment Video
Updated: Jun 28, 2026
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
Malignancy as a rising contributor to mortality in patients with inflammatory bowel disease: a population-based
Amr Ahmed Aly Ibrahim1,2, Mahmoud Shaaban Abdelgalil3,4, Sara Hosny El-Farargy5,2
1Faculty of Medicine, Menoufiya University, Menoufiya, Egypt.
Background:
Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), is associated with increased malignancy risk. This study assessed national trends in malignancy-related mortality among United States IBD patients from 1999 to 2020 using representative data.
Methods:
A retrospective, population-based analysis was conducted using the Centers for Disease Control and Prevention (CDC) Wide-ranging Online Data for Epidemiologic Research (WONDER) database. Deaths among individuals with IBD were identified using ICD-10 codes K50 and K51, while malignancy-related deaths were captured using codes C00-C97. Crude and Age-adjusted mortality rates (AMRs) were calculated and stratified by sex, ethnicity, region, state, and age group. Linear regression models evaluated trends and forecast malignancy-related mortality through 2030.
Results:
Between 1999 and 2020, 9,531 malignancy-related deaths occurred among IBD patients. Malignancy-related deaths rose significantly, increasing by 108.3% (p = 0.010, R2 = 0.439). Higher AMRs were observed among males (p = 0.009), White individuals (p = 0.019), Midwest residents (p = 0.015), and patients aged ≥ 65. The largest relative increases were among females (55.2%), White individuals (55.1%), West residents (75.2%), and those aged 65-74 years (72.6%). Lung and colon cancers were the leading causes of malignancy-related deaths. Projections suggest continued rises in malignancy-related AMRs, particularly among CD patients, while UC patients remain relatively stable.
Conclusion:
Malignancy is an increasingly important contributor to mortality among US IBD patients, particularly older adults, males, Midwest residents and White individuals. These findings highlight the need for enhanced cancer surveillance, equitable healthcare access, and integrated long-term management of IBD populations.
Related Concept Videos
01:25Inflammatory Bowel Disease III: Crohn's Disease
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
01:20Inflammatory Bowel Disease IV: Clinical Manifestations
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
01:26Inflammatory Bowel Disease I: Introduction